Interim Canadian recommendations for the use of fractional dose of yellow fever vaccine during a vaccine shortage

An Advisory Committee Statement (ACS)
Committee to Advise on Tropical Medicine and Travel (CATMAT)

Table of contents

Preamble

The Committee to Advise on Tropical Medicine and Travel (CATMAT) provides the Public Health Agency of Canada with ongoing and timely medical, scientific, and public health advice relating to tropical infectious disease and health risks associated with international travel. The Agency acknowledges that the advice and recommendations set out in this statement are based upon the best current available scientific knowledge and medical practices, and is disseminating this document for information purposes to both travellers and the medical community caring for travellers.

Persons administering or using drugs, vaccines, or other products should also be aware of the contents of the product monograph(s) or other similarly approved standards or instructions for use. Recommendations for use and other information set out herein may differ from that set out in the product monograph(s) or other similarly approved standards or instructions for use by the licensed manufacturer(s). Manufacturers have sought approval and provided evidence as to the safety and efficacy of their products only when used in accordance with the product monographs or other similarly approved standards or instructions for use.

Summary

This statement outlines interim recommendations intended for use during yellow fever vaccine shortages only. The recommendations differ from the standard recommendations for yellow fever vaccination in the Canadian Immunization Guide and in the Committee to Advise on Tropical Medicine and Travel (CATMAT) Statement for Travellers and Yellow Fever.

Introduction

Yellow fever vaccine shortages pose a challenge. Travel clinics may be allotted a small fraction of the number of vaccines typically ordered, or in some cases, travel clinics will not have access to the yellow fever vaccine until a new supply of the vaccine is available. There is currently only one licensed marketer of the vaccine in Canada.

In 2016, there were calls for the use of a fractional dose of yellow fever vaccine to address a global yellow fever vaccine shortage, a measure which would allow for immunization of a greater number of people during the vaccine shortage. This suggestion is primarily based on three studies which have shown that doses in the range of 1/10 to 1/5 of the usual 0.5 ml subcutaneous dose are protective based on laboratory criteriaFootnote 1 Footnote 2 Footnote 3.

On 17 June 2016, the World Health Organization (WHO) released a statement that the WHO Strategic Advisory Group of Experts (SAGE) on Immunization found that the use of a fifth of a standard vaccine dose (0.1ml instead of 0.5ml) would provide protection against yellow fever for at least 12 months based on a review of existing evidenceFootnote 4.The WHO states that the fractional dose of yellow fever vaccine can be considered a safe and effective approach to control an urban outbreak in case of vaccine shortages.

CATMAT formed a working group to review the evidence and make interim recommendations on the use and documentation of fractional doses of yellow fever vaccine in Canada intended for use during yellow fever vaccine shortages only. Each member was a volunteer, and none declared a relevant conflict of interest. The recommendations differ from the standard recommendations for yellow fever vaccination in the Canadian Immunization GuideFootnote 5 and in the Committee to Advise on Tropical Medicine and Travel (CATMAT) Statement for Travellers and Yellow FeverFootnote 6.

Methods

A literature search for evidence related to the immunogenicity of a fractional dose of yellow fever vaccine was conducted. Evidence was retrieved by performing searches in electronic databases (Ovid MEDLINE, Embase, Global Health and Scopus). The search spanned the initial date for each database until June 2016 and 49 results were identified. Titles and abstracts of these results were reviewed and selected for inclusion based on relevancy to the research question. In December 2016, the literature search was updated to capture any new publications since June 2016; no new articles were identified.

Results

In 2008, Roukens et al. studied the effect of a one-fifth dose of yellow fever vaccine administered intradermally. All subjects developed titers of neutralizing antibody considered to be protectiveFootnote 7. The average subject age was 27 years with a wide adult age range (18 to 70 years).

In 2013, Martins et al. studied seroconversion and viremia responses to the use of full dose and five different dilutions of the usual human dose of 17-DD yellow fever vaccine administered subcutaneouslyFootnote 8. There was little difference in immune response down to a dilution of 1:50.

In a 2014 extension of the Martins study (using the same patient data and collected blood); Campi-Azevedo et al. studied serum biomarkers of cellular immunity responses using fractional dosesFootnote 9. There was evidence of protection at dilutions down to 1:50. However, consistent findings of equivalency to a full dose across all markers of immunity (serology, viremia and cellular immunity) were found down to a 1:10 dilution. In the Martins and Campi-Azevedo investigations, all subjects were healthy young males with an average age of 19 years.

Although the results of these studies are encouraging, this constitutes a limited evidence base. Further research is needed to determine the effectiveness of fractional doses, especially in young children.

Recommendations

Under normal circumstances, a recommendation for use of fractional dose of yellow fever vaccine would not be made for travellers. In the event of a shortage, some travellers going to yellow fever endemic or epidemic regions may not have access to a full dose of yellow fever vaccine, and as such, these travellers face the choice of not receiving a vaccine or receiving a fractional dose of vaccine.

In view of this situation, CATMAT makes the following recommendation, applicable to individuals for whom the standard yellow fever vaccine recommendations apply, including young children:

  • For travel to a region of a country with risk of yellow fever, health care professionals should first emphasize the importance of receiving a full dose of vaccine or otherwise postponing the trip. This is especially critical for travel to areas experiencing an ongoing outbreak of the disease.
  • If a traveller must travel to an endemic area, especially to areas experiencing an ongoing outbreak of yellow fever, and a full dose cannot be located after reasonable efforts, a fractional dose may be administered. The dose should be 1/5 of the usual dose (0.1 ml instead of 0.5 ml) administered by the traditional subcutaneous route. As with full dose, a fractional dose is considered protective 10 days after it is administered to a person who has never before received the yellow fever vaccine.
  • If a traveller planning a high risk itinerary receives a fractional dose of yellow fever vaccine, and then later finds that a full dose has become available, this dose may be administered and the International Certificate of Vaccination or Prophylaxis (ICVP) may be issued.
  • Once reconstituted, the vaccine vial should be stored between 2° and 8° Celsius, and used within one hour. Thus, it will be necessary to vaccinate several people within that hour in order to efficiently use the contents of the vial in the allotted time. The health care professional may find that the use of disposable 1 cc insulin syringes with a non-detachable needle wastes less vaccine. Four, possibly five, doses may be obtained from one vial. Strict aseptic technique should be observed.
  • If fewer than five doses are being administered, it is recommended that the entire contents of the vial be used, equally distributed among those being immunized. This will allow for the administration of somewhat more than 0.1 ml per person.
  • Based on available data, a fractional dose (1/5) (0.1 ml instead of 0.5 ml) should be considered protective for one year. Protection may be longer, however long term data is lacking. No recommendation is made at this time regarding repeat fractional dose immunization for subsequent travel.
  • Once the supply of yellow fever vaccine is restored in Canada, the use of fractional doses should be discontinued.
  • Practitioners are reminded that the WHO now considers a single full dose of yellow fever vaccine protective for life regardless of when it is administered.
  • There is very little data on seropositivity using fractional doses in travellers who are HIV+, pregnant (and in whom a risk evaluation concludes immunization is appropriate) or under 2 years of age. However the potency of a 1/5th dose of YF-Vax would still exceed the minimum vaccine potency recommended by WHO. The clinician should in all cases weigh the risk of yellow fever exposure and availability of vaccine when deciding whether or not to use fractional dosing.

Documentation of Fractional Dose Yellow Fever Vaccination

The WHO states that a fractional dose of the yellow fever vaccine would not qualify for a yellow fever certificate under the International Health Regulations (IHR)Footnote 4. Therefore CATMAT does not recommend that practitioners use the official International Certificate of Vaccination or Prophylaxis (ICVP) card to document a fractional dose.

One option for documentation is the use of the Certificate of Medical Contraindication to Vaccination provided by the Public Health Agency of Canada. An explanation can be written inside informing that a fractional dose of 0.1ml of the yellow fever vaccine was administered subcutaneously due to a severe vaccine shortage.

Additional resources and useful links

Acknowledgements

This statement was developed by the Yellow Fever Working Group: Teitelbaum P (chair), Bui Y, Libman M, Pernica J, and approved by CATMAT

CATMAT acknowledges and appreciates the contribution of Mona Abdel-Motagally and Elspeth Payne to this statement.

CATMAT members: McCarthy A (Chair), Acharya A, Boggild A, Brophy J, Bui Y, Crockett M, Greenaway C, Libman M, Teitelbaum P and Vaughan S.

Liaison members: Angelo, K (United States Centers for Disease Control and Prevention), Audcent T (Canadian Paediatric Society) and Pernica J (Association of Medical Microbiology and Infectious Disease Canada).

Ex officio members: Marion D (Canadian Forces Health Services Centre, Department of National Defence), McDonald P (Bureau of Medical Sciences, Health Canada), Rossi C (Directorate of Force Health Services Group,Department of National Defence), and Schofield S (Pest Management Entomology, Department of National Defence).

Conflict of interest

None declared.

Report a problem or mistake on this page
Please select all that apply:

Privacy statement

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: